Medication Monitor



SORT BY:      Most Recent      Most Viewed     
List-View      Table-View
Generic Name (Trade Name—Company)
Notes
  • January 1, 2011

    Uses:

    Treatment of mild to moderate pain and moderate to severe pain with adjunctive opioid analgesics and for the reduction of fever in patients 2 years and older

    This is the first and only I.V. form of acetaminophen approved by FDA. It can be given as a single dose or as repeated doses. The recommended dose for adults and adolescents weighing 50 kg or more is 1,000 mg every 6 hours or 650 mg every 4 hours to a maximum of 4,000 mg/d. For adults and adolescents weighing less than 50 kg, and for children 2–12 years old, the recommended dose is 15 mg/kg every 6 hours or 12.5 mg/kg every 4 hours to a maximum of 75 mg/kg/d. This new formulation will be marketed in 100-mL glass vials containing 1,000 mg of acetaminophen.

  • January 1, 2011

    Uses:

    Treatment of metastatic breast cancer

    Eribulin is a nontaxane microtubule dynamics inhibitor indicated for patients who have previously received at least two chemotherapeutic regimens for treatment of their metastatic breast cancer. The recommended dose is 1.4 mg/m2 given I.V. over 2 to 5 minutes on days 1 and 8 of a 21-day cycle. FDA approved the drug based on data from an open-label trial showed that treatment with eribulin improved overall survival compared with a control treatment regimen, resulting in a median response duration of 4.2 months. Common adverse events observed with therapy were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.

  • January 1, 2011

    Uses:

    Treatment of lipodystrophy in patients with HIV

    Tesamorelin is a synthetic analogue of growth hormone–releasing factor, administered once daily as a 2-mg subcutaneous injection, which has been shown to reduce abdominal fat in patients with HIV. Two 26-week studies with 26-week extension phases conducted in 816 patients with HIV and lipodystrophy with excess abdominal fat provided the basis for FDA approval. Patients randomized to tesamorelin had 14% to 18% reductions in visceral adipose tissue, compared with minimal changes in the placebo group. The most commonly reported adverse events included arthralgia, injection site erythema and pruritus, pain in extremity, peripheral edema, and myalgia. Other safety concerns with tesamorelin include induction of supraphysiological levels of insulin-like growth factor 1, which may affect the development of malignancies, glucose intolerance, and fluid retention.

  • July 7, 2002

    Uses:

    Management of seizures and a variety of pain conditions

    Lupin Pharmaceuticals announced that it has received FDA approval to market its generic version of Pfizer’s Lyrica capsules. The pregabalin capsules are AB rated to Pfizer's product and will be available in 25-, 50-, 75-, 100-, 150-, 200-, 225-, and 300-mg strengths.

    Pregabalin is indicated for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures, neuropathic pain associated with spinal cord injury, and fibromyalgia.

Pages